Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

PF-06821497 Behandeling van recidiverende/refractaire SCLC, castratieresistente prostaatkanker en folliculair lymfoom

9 november 2026 bijgewerkt door: Pfizer

EEN FASE I DOSIS ESCALATIE EN UITGEBREID COHORTONDERZOEK VAN PF-06821497 BIJ DE BEHANDELING VAN VOLWASSEN PATIËNTEN MET TERUGVALLEN/REFRACTAIRE KLEINCELLONGKANKER (SCLC), CASTRATIERESISTENTE PROSTAATKANKER (CRPC) EN FOLLICULAIR LYMFOMA (FL)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.

Part 3, which is open for enrollment is seeking men who:

  • have Castration Resistant Prostate Cancer (CRPC) and
  • have previously received treatment for CRPC and have progressed from the last treatment

All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).

In the assessment phase:

  • participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
  • participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
  • participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.

After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.

The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Studie Overzicht

Gedetailleerde beschrijving

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).

Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.

Studietype

Ingrijpend

Inschrijving (Geschat)

453

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Haskovo, Bulgarije, 6300
        • Beëindigd
        • Specialized Hospital for Active Treatment of Oncology - Haskovo
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Actief, niet wervend
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, China, 410013
        • Actief, niet wervend
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, China, 210009
        • Actief, niet wervend
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, China, 210008
        • Actief, niet wervend
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Werving
        • West China Hospital, Sichuan University
    • Zhejiang
      • Wenzhou, Zhejiang, China, 325000
        • Actief, niet wervend
        • The First Affiliated Hospital of Wenzhou Medical University
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Actief, niet wervend
        • National Cancer Center Hospital East
      • Bydgoszcz, Polen, 85-048
        • Nog niet aan het werven
        • In-Vivo Sp. z o.o. In-vivo Bydgoszcz
      • Koszalin, Polen, 75-581
        • Actief, niet wervend
        • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
      • Krakow, Polen, 30-348
        • Werving
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Rzeszów, Polen, 35-326
        • Actief, niet wervend
        • Centrum Medyczne MEDYK
      • Warsaw, Polen, 02-781
        • Actief, niet wervend
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
      • Moscow, Rusland, 117186
        • Actief, niet wervend
        • LLC "Neyro-klinika"
      • Moscow, Rusland, 125284
        • Beëindigd
        • Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
      • Moscow, Rusland, 129301
        • Beëindigd
        • SBHI of Moscow City Clinical Hospital
      • Omsk, Rusland, 644013
        • Beëindigd
        • Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
      • Saint Petersburg, Rusland, 197341
        • Beëindigd
        • Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
      • Saint Petersburg, Rusland, 197758
        • Beëindigd
        • Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
      • Saint Petersburg, Rusland, 198255
        • Beëindigd
        • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
      • Yaroslavl, Rusland, 150054
        • Beëindigd
        • State Budgetary Healthcare Institution of the Yaroslavl Region
    • Sankt-Peterburg
      • Pushkin, Sankt-Peterburg, Rusland, 196603
        • Actief, niet wervend
        • Private Medical Institution "Euromedservice"
      • Barcelona, Spanje, 08035
        • Werving
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spanje, 08036
        • Werving
        • Hospital Clinic de Barcelona
      • Barcelona, Spanje, 08023
        • Werving
        • Hospital Quironsalud Barcelona
      • Madrid, Spanje, 28034
        • Werving
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spanje, 28050
        • Werving
        • Hospital Universitario HM Sanchinarro
      • Madrid, Spanje, 28040
        • Werving
        • H.U. Fundación Jiménez Díaz
      • Madrid, Spanje, 28041
        • Werving
        • Hospital Universitario 12 De Octubre
      • Málaga, Spanje, 29010
        • Werving
        • Hospital Universitario Virgen de la Victoria
      • Valencia, Spanje, 46026
        • Actief, niet wervend
        • Hospital Universitari i Politecnic La Fe
    • Barecelona
      • L'Hospitalet de Llobregat, Barecelona, Spanje, 08908
        • Actief, niet wervend
        • Institut Català d´Oncología (ICO)-H. Durán i Reynals
    • Castellon
      • Castellon, Castellon, Spanje, 12002
        • Actief, niet wervend
        • Consorcio Hospitalario Provincial de Castellon
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanje, 28223
        • Werving
        • Hospital Quironsalud Madrid
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spanje, 28040
        • Werving
        • Hospital Clinico San Carlos
    • Arizona
      • Tucson, Arizona, Verenigde Staten, 85719
        • Actief, niet wervend
        • Banner-University Medical Center Tucson
      • Tucson, Arizona, Verenigde Staten, 85719
        • Actief, niet wervend
        • The University of Arizona Cancer Center-North Campus
      • Tucson, Arizona, Verenigde Staten, 85724
        • Actief, niet wervend
        • The University of Arizona Cancer Center
      • Tucson, Arizona, Verenigde Staten, 85741
        • Beëindigd
        • Arizona Urology Specialists, PLLC
    • California
      • Anaheim, California, Verenigde Staten, 92801
        • Actief, niet wervend
        • Pacific Cancer Medical Center INC
      • Duarte, California, Verenigde Staten, 91010
        • Actief, niet wervend
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte, California, Verenigde Staten, 91010
        • Actief, niet wervend
        • City of Hope Investigational Drug Services (IDS)
    • Connecticut
      • Norwalk, Connecticut, Verenigde Staten, 06856
        • Actief, niet wervend
        • Norwalk Hospital
    • Kansas
      • Fairway, Kansas, Verenigde Staten, 66205
        • Actief, niet wervend
        • The University of Kansas Cancer Center, Investigational Drug Services
      • Fairway, Kansas, Verenigde Staten, 66205
        • Actief, niet wervend
        • The University of Kansas Clinical Research Center
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Actief, niet wervend
        • The University of Kansas Hospital
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Actief, niet wervend
        • The University of Kansas Medical Center Medical Office Building
      • Overland Park, Kansas, Verenigde Staten, 66211
        • Actief, niet wervend
        • The University of Kansas Cancer Center - Indian Creek Campus
      • Westwood, Kansas, Verenigde Staten, 66205
        • Actief, niet wervend
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Actief, niet wervend
        • Norton Cancer Institute, Norton Healthcare Pavilion
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Actief, niet wervend
        • Norton Hospital
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Actief, niet wervend
        • Norton Cancer Institute - Downtown
    • Maryland
      • Rockville, Maryland, Verenigde Staten, 20850
        • Beëindigd
        • Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Actief, niet wervend
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Actief, niet wervend
        • Brigham and Women's Hospital
      • Newton, Massachusetts, Verenigde Staten, 02459
        • Actief, niet wervend
        • Dana Farber Cancer Institute- Chestnut Hill
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68130
        • Werving
        • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    • New Jersey
      • Hackensack, New Jersey, Verenigde Staten, 07601
        • Actief, niet wervend
        • Hackensack University Medical Center
      • Hackensack, New Jersey, Verenigde Staten, 07601
        • Actief, niet wervend
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • OU Health University of Oklahoma Medical Center
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • Stephenson Cancer Center (chemo location)
    • South Carolina
      • Myrtle Beach, South Carolina, Verenigde Staten, 29572
        • Werving
        • Carolina Urologic Research Center
      • Myrtle Beach, South Carolina, Verenigde Staten, 29572
        • Werving
        • Parkway Surgery Center
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Beëindigd
        • Texas Oncology - Austin Midtown
      • Dallas, Texas, Verenigde Staten, 75390
        • Actief, niet wervend
        • UT Southwestern Medical Center
      • Dallas, Texas, Verenigde Staten, 75390
        • Actief, niet wervend
        • University of Texas Southwestern Medical Center - Simmons Cancer Center
      • Dallas, Texas, Verenigde Staten, 75390
        • Actief, niet wervend
        • UT Southwestern University Hospital - William P. Clements, Jr
      • Dallas, Texas, Verenigde Staten, 75390
        • Actief, niet wervend
        • UT Southwestern University Hospital - Zale Lipshy
      • Irving, Texas, Verenigde Staten, 75063
        • Beëindigd
        • US Oncology Investigational Product Center (IPC)
      • Irving, Texas, Verenigde Staten, 75063
        • Beëindigd
        • US Oncology Investigational Products Center
      • Irving, Texas, Verenigde Staten, 75039
        • Werving
        • NEXT Dallas
      • San Antonio, Texas, Verenigde Staten, 78229
        • Werving
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • Actief, niet wervend
        • Virginia Cancer Specialists, PC
    • Washington
      • Port Angeles, Washington, Verenigde Staten, 98362
        • Actief, niet wervend
        • Olympic Medical Center
      • Poulsbo, Washington, Verenigde Staten, 98370
        • Actief, niet wervend
        • Fred Hutchinson Cancer Center Alliance Peninsula
      • Seattle, Washington, Verenigde Staten, 98195
        • Actief, niet wervend
        • University of Washington Medical Center
      • Seattle, Washington, Verenigde Staten, 98109
        • Actief, niet wervend
        • Fred Hutchinson Cancer Center
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Zuid -Korea, 13620
        • Werving
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul, Seoul-teukbyeolsi [seoul], Zuid -Korea, 03080
        • Actief, niet wervend
        • Seoul National University Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Zuid -Korea, 07985
        • Actief, niet wervend
        • Ewha Womans University Mokdong Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Zuid -Korea, 03722
        • Actief, niet wervend
        • Severance Hospital, Yonsei University Health System
    • Taejǒn-kwangyǒkshi
      • Daejeon, Taejǒn-kwangyǒkshi, Zuid -Korea, 35015
        • Actief, niet wervend
        • Chungnam national university hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

  • Histological or cytological diagnosis of castration resistant prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
  • Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

  • Prior irradiation to >25% of the bone marrow.
  • QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
  • Prior enzalutamide within the last 4 weeks
  • DDI SUBSTUDY:
  • history of CHF or evidence of ventricular dysfunction
  • fructose intolerance
  • coadministration of CYP3A4 substrates
  • Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dose Escalation (Part 1A)

Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels

Oral continuous

Andere namen:
  • EZH2i
Experimenteel: Dose Escalation (Part 1B)

Participants with FL will receive mevrometostat at escalating dose levels

Oral continuous

Andere namen:
  • EZH2i
Experimenteel: Dose Escalation (Part 1C)

Participants with mCRPC will receive mevrometostat at escalating dose levels.

Oral continuous

Andere namen:
  • EZH2i
Experimenteel: Dose Escalation (Part 2A)

Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.

Oral continuous

Andere namen:
  • EZH2i

Oral continuous

Andere namen:
  • Xtandi
Experimenteel: Dose Expansion (Part 2B)

Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.

Oral continuous

Andere namen:
  • EZH2i

Oral continuous

Andere namen:
  • Xtandi
Experimenteel: Japan Cohort

Participants with CRPC will receive mevrometostat at one or two doses

Oral continuous

Andere namen:
  • EZH2i
Experimenteel: China cohort

Participants will receive mevrometostat at one or two doses

Oral continuous

Andere namen:
  • EZH2i
Experimenteel: Dose Expansion (Part 2C)

Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC

Oral continuous

Andere namen:
  • EZH2i

Oral continuous

Andere namen:
  • Xtandi
Experimenteel: BE Substudy

In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andere namen:
  • EZH2i

Oral continuous

Andere namen:
  • Xtandi
Experimenteel: DDI Substudy

The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andere namen:
  • EZH2i

Oral continuous

Andere namen:
  • Xtandi

Oral solution

Andere namen:
  • Sporanox
  • Tolsoera
  • Onmel

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Tijdsspanne: Baseline up to 90 days

First cycle DLTs will be utilized to determine the MTD

Baseline up to 90 days
Overall safety profile including adverse events
Tijdsspanne: Baseline up to approximately 2 years

Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03])

Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
Tijdsspanne: Through study completion, approximately 2 years past last patient first visit.

Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.

Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
Tijdsspanne: Baseline up to approximately 2 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing.

Baseline up to approximately 2 years
Overall safety profile including vital signs
Tijdsspanne: Baseline up to approximately 2 years

Vital sign changes from baseline including blood pressure, heart rate, ECG changes.

Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Tijdsspanne: Baseline until disease progression or death or through study completion (approx 2 years)

PCWG3

Baseline until disease progression or death or through study completion (approx 2 years)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Tijdsspanne: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.

Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)

Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
Evaluate overall survival
Tijdsspanne: Baseline up to approximately 2 years

Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.

Baseline up to approximately 2 years
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Tijdsspanne: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Singe dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Evaluate the impact of mevrometostat on patient reported outcomes.
Tijdsspanne: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.

Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.

At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Tijdsspanne: At specific time points from Cycle1 Day 1 to end of treatment

Questionnaire customized from PRO-CTCAE.

At specific time points from Cycle1 Day 1 to end of treatment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Pfizer CT.gov Call Center, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

17 april 2018

Primaire voltooiing (Geschat)

20 april 2028

Studie voltooiing (Geschat)

7 juli 2029

Studieregistratiedata

Eerst ingediend

12 februari 2018

Eerst ingediend dat voldeed aan de QC-criteria

2 maart 2018

Eerst geplaatst (Werkelijk)

9 maart 2018

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren